Loading...
XNYS
BHC
Market cap2.26bUSD
Oct 08, Last price  
6.04USD
1D
-1.79%
1Q
26.36%
Jan 2017
-58.40%
Name

Bausch Health Companies Inc

Chart & performance

D1W1MN
XNYS:BHC chart
P/E
14.39
P/S
0.22
EPS
0.42
Div yield, %
—
Shrs. gr., 5y
1.10%
Rev. gr., 5y
5.04%
Revenues
10.27b
+6.66%
1,070,475,000842,818,000757,178,000820,430,0001,146,128,0002,463,450,0003,480,400,0005,765,600,0008,200,000,00010,442,000,0009,674,000,0008,724,000,0008,380,000,0008,601,000,0008,027,000,0008,434,000,0008,124,000,0008,757,000,0009,625,000,00010,266,000,000
Net income
157m
P
210,004,059195,539,000199,904,000176,455,000-208,193,000159,559,000-116,025,000-866,142,000881,000,000-268,658,802-2,409,000,0002,404,000,000-4,148,000,000-1,783,000,000-559,000,000-948,000,000-225,000,000-592,000,000-46,000,000157,000,000
CFO
1.40b
-12.34%
521,934,000340,853,000204,325,000360,897,000263,191,000676,473,000656,578,0001,041,957,0002,294,700,0002,200,400,0002,087,000,0002,290,000,0001,501,000,0001,501,000,0001,111,000,0001,426,000,000-728,000,0001,032,000,0001,597,000,0001,400,000,000
Dividend
Nov 10, 20101 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.

Related entities

Subsidiaries (4)
BAUSCH & LOMB INDIA PRIVATE LIMITED
Bausch & Lomb Incorporated
Bausch+Lomb Netherlands B.V.

Key people

John Paulson
Independent Non-Executive Chairman of the Board · since 2022
Jean-Jacques Charhon
Executive Vice President, Chief Financial Officer · since 2025
Aimee Lenar
Executive Vice President, US Pharma · since 2024
John Barresi
Senior Vice President, Chief Accounting Officer, Controller · since 2024
Seana Carson
Executive Vice President, General Counsel · since 2022
Steven Lee
Senior Vice President, Controller, Chief Accounting Officer · since 2025
Thomas Appio
Chief Executive Officer, Director · since 2022
Michael Goettler
Director · since 2025
Sandra Leung
Director · since 2025
Independent Director · since 2024
Independent Director · since 2016
Independent Director · since 2024
Steven Miller
Independent Director · since 2021
Richard Mulligan
Independent Director · since 2022
John Paulson
Independent Non-Executive Chairman of the Board · since 2022
Robert Power
Independent Director · since 2008
Amy Wechsler
Independent Director · since 2016
IPO date
Sep 20, 1994
Employees
19,900
Domiciled in
CA
Incorporated in
CA
Legal address
1055 WEST HASTINGS STREET
SUITE 1700
Vancouver, BC V6E 2E9
CA
Headquarters
2150 Saint Elzéar Boulevard West
Laval, QC H7L 4A8
CA
Previous name
BIOVAIL CORPORATION
Previous name
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT